CTOs on the Move

BrainsWay

www.brainsway.com

 
BrainsWay is an Israeli company with international operations that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation as a noninvasive treatment for depression.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.brainsway.com
  • 1 Van de Graaff Drive Suite 405
    Burlington, MA USA 01803
  • Phone: 844.386.7001

Executives

Name Title Contact Details

Similar Companies

Triangle Compounding Pharmacy

Triangle Compounding Pharmacy is a Cary, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tetraphase

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.

Blue Sky Broadcast

Blue Sky Broadcast is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Retia Medical

Retia Medical provides accurate, simple, low-cost cardiac output monitoring.

Aridis Pharmaceuticals

Aridis is a privately held biotechnology company located in San Jose, CA, USA which is focused on infectious diseases. Aridis has a strong portfolio of anti-infective product candidates, a human monoclonal antibody discovery platform technology, and best-in-class formulation technologies available for partnering. Our product portfolio comprises two monoclonal antibodies currently at Phase 2 clinical testing in patients, and two additional anti-infective drug candidates entering the IND development stage. Aridis’ suite of anti-infective monoclonal antibodies offers opportunities to profoundly impact current approaches to infection control. Aridis has raised over $20m in grant funding from leading institutions such as the National Institutes of Health, US Dept. of Defense, US Dept. of Health and Human Services’ BARDA, USAID, PATH/Gates Foundations, and Regional Centers of Excellence.